SCHEMBL25756589

SCHEMBL25756589

CCN1C(=O)C(=O)c2ccc(Br)c(OC)c21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1B1 Q16678 2/20 0.46
PARK7 Q99497 3/20 0.44
CES1 P23141 2/20 0.43
CASP3 P42574 1/20 0.41
CASP7 P55210 1/20 0.41
MAPT P10636 2/20 0.39
HTT P42858 2/20 0.39
ALDH1A1 P00352 1/20 0.39
HSD17B10 Q99714 1/20 0.39
POLB P06746 1/20 0.38
CUL4A Q13619 1/20 0.38
CHRM5 P08912 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
TP53 P04637 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
LMNA P02545 1/20 0.36
HPGD P15428 1/20 0.36
CGAS Q8N884 1/20 0.36
TSHR P16473 1/20 0.36
APOBEC3A P31941 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25756618 0.82 MEN1 (0.46) CYP1B1PARK7CES1CASP3MAPT
SCHEMBL17165877 0.80 CYP1B1 (0.49) CYP1B1PARK7CES1CASP3CASP7
SCHEMBL27199609 0.78 MAPT (0.40) PARK7CES1MAPTHTTALDH1A1
SCHEMBL25756617 0.74 RORC (0.40) PARK7CES1MAPTHTTALDH1A1
SCHEMBL19630025 0.72 PARK7 (0.50) CYP1B1PARK7CES1CASP3CASP7
SCHEMBL30665942 0.71 PARK7 (0.49) CYP1B1PARK7CES1CASP3CASP7
SCHEMBL26654540 0.71 PARK7 (0.49) CYP1B1PARK7CES1CASP3CASP7
SCHEMBL25756590 0.70 KMT2A (0.34) CYP1B1MAPTALDH1A1SMN1; SMN2
SCHEMBL7519554 0.69 DRD2 (0.34) CYP1B1MAPTALDH1A1CHRM5SMN1; SMN2
SCHEMBL31003772 0.68 PARK7 (0.53) CYP1B1PARK7CASP3MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO LTD (CN) 2025-04-10 US disclosed
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-10-29 US disclosed
EP-4448514-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF Lynk Pharmaceuticals Co. Ltd. (CN) 2024-10-23 EP disclosed
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-04-18 US disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 WO disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 CYP1B1 3838/4885PARK7 646/4885CES1 3436/4885
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 CYP1B1 3838/4885PARK7 646/4885CES1 3436/4885
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof TYK2, JAK2, JAK1 CYP1B1 3838/4885PARK7 646/4885CES1 3436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.